TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05637385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training of perception and oculo-motor control
Description: Behavioral training of eye movements and perception

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training of perception and oculo-motor control
Description: Behavioral training of eye movements and perception
Study: NCT05392153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial therapy
Description: Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
Study: NCT05363423

Intervention type: PROCEDURE
Intervention: Draf III procedure with lateral pedicled nasoseptal flaps applied
Description: The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table.

Intervention type: PROCEDURE
Intervention: Draf III procedure without any flap applied
Description: The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre.
Study: NCT06373367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text based application
Description: Standard preeclampsia discharge instructions
Study: NCT06025864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months.
Study: NCT05073874

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Near-Infrared Spectroscopy (fNIRS)
Description: The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Study: NCT06294106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)
Description: EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)
Description: EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
Study: NCT04725578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Single Session Consultation
Description: A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
Study: NCT04740008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Nicotine Content Cigarettes
Description: Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Nicotine Content Cigarettes
Description: Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control message
Description: Participants will read control message

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test message
Description: Participants will read test message
Study: NCT05072236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopic insertion
Description: After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopic insertion
Description: After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bronchoscopic insertion
Description: After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
Study: NCT06236269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
Study: NCT03826303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette liquid with ethanol, 1 puff
Description: E-cigarette liquid with ethanol, 1 puff

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-cigarette liquid without ethanol, 1 puff
Description: E-cigarette liquid without ethanol, 1 puff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette liquid with ethanol, 10 puffs
Description: E-cigarette liquid with ethanol, 10 puffs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-cigarette liquid without ethanol, 10 puffs
Description: E-cigarette liquid without ethanol, 10 puffs
Study: NCT05604170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: GNX will be administered.
Study: NCT04958473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
Study: NCT04976400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: semi-individualized total knee replacement treatment with a gender-specific design
Description: Patients in the experimental group received a semi-individualized total knee replacement treatment with a gender-specific design.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA)
Description: Patients in the control group received imported Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA).
Study: NCT04682366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral drug: 10 days of 0.4 mg of oral Tamsulosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drug: 10 days of identical-appearing placebo
Study: NCT05694754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
Study: NCT06023082

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colon Broom Premium supplement
Description: The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron
Study: NCT05781919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality imaging
Description: Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gold standard imaging
Description: Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
Study: NCT06096896

Intervention type: PROCEDURE
Intervention: MWA
Description: Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
Study: NCT06190678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study: NCT04751708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular treatment
Description: For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical management
Description: best medical management
Study: NCT06429475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair).~The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
Study: NCT06524752

Intervention type: OTHER
Intervention: The presence of nausea and vomiting within 24 hours after surgery
Description: This is a prospective risk prediction model building, thus there is no traditional definition of intervention.

Intervention type: OTHER
Intervention: Non-existence of nausea and vomiting within 24 hours after surgery
Description: This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
Study: NCT04921137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No endocrine therapy
Description: No endocrine therapy given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Endocrine therapy given for at least 5 years
Study: NCT04994288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: placebo injection 0.5ml
Study: NCT05679752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial PNF technique
Description: Stimulation techniques used to facilitate the weak muscle groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: frictional massage to stimulate the weak muscle groups
Study: NCT05927857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI /Experimental
Description: infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab /Experimental
Description: infusional 8mg/kg over 60 minutes day 1, every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil /Experimental
Description: oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
Study: NCT03616041

Intervention type: DEVICE
Intervention: Second-generation colon capsule endoscopy system
Description: The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
Study: NCT06341257

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Central/Core Ablative Radiation Therapy (SCART)
Description: The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor GTV boundary.
Study: NCT05021406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 MG
Description: Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
Study: NCT04098718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 100mg sub cut once only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 100mg sub cut once only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 30mg tablet daily for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: 30mg tablet daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 30mg tablet daily for 5 days
Study: NCT04846738

Intervention type: DEVICE
Intervention: Transcranial Doppler
Description: This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),

Intervention type: DEVICE
Intervention: Pupillometry.
Description: This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
Study: NCT04907136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred ENDS
Description: Preferred ENDS without HWL on device
Study: NCT05831930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nituozumab
Description: Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
Study: NCT04708756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collabree Mobile Phone Application Medication Adherence Booster (simplified version)
Description: Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collabree Mobile Phone Application Medication Adherence Booster
Description: Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
Study: NCT04907136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred ENDS
Description: Preferred ENDS without HWL on device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred ENDS with HWL
Description: Preferred ENDS with a HWL on device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred ENDS with HWL
Description: Preferred ENDS with a HWL on device
Study: NCT04690049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular resistance exercise program
Description: This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control exercise program with elastic band
Description: This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks.
Study: NCT04892381

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: * Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: * Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP
Study: NCT06361069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction cards, kaleidoscope and finger puppet
Description: A kaleidoscope, characterized by vibrant patterns visible through rotation of its cylinders, operates on the principle of light refraction, producing dynamic and ever-changing visual displays.~Distraction cards feature an array of images and shapes, each measuring approximately 5-8 cm in length. These intricate designs are discernible only upon careful examination of the cards.~Puppets, as a therapeutic intervention tool, significantly influence children's personal, social, and emotional development, facilitating their comfortable expression of emotions.
Study: NCT05467397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]acetate
Description: Positron Emission Tomography (PET)
Study: NCT05350631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OnKO-Tips&Tricks digital phone application
Description: Using daily OnKO-Tips\&Tricks digital phone application
Study: NCT04823221

Intervention type: DEVICE
Intervention: Rezūm System
Description: The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
Study: NCT06418828

Intervention type: OTHER
Intervention: return to work
Description: Ask patients if they are going back to work

Intervention type: OTHER
Intervention: return to work
Description: Ask patients if they are going back to work